Genzyme gets patent and launches bypass instruments
This article was originally published in Clinica
Executive Summary
Genzyme General Division, the largest division of US biotech company Genzyme, has been issued a US patent for its new mutation detection technology. Multiple Allele-Specific Diagnostic Assay (MASDA) is the first technology to allow simultaneous analysis of hundreds of DNA samples for more than 100 mutations on one or more genes in a single test. MASDA uses a two-step approach. In the first step, samples that are negative for certain mutations are eliminated. In the second step, specific mutations are identified in positive samples.